<DOC>
	<DOCNO>NCT02822235</DOCNO>
	<brief_summary>The purpose study gather information regard population moderate severe inflammatory bowel disease ( IBD ) , burden disease , understand treatment pattern , particularly use available biologic therapy .</brief_summary>
	<brief_title>Non-interventional Study Moderate Severe Inflammatory Bowel Disease Brazil</brief_title>
	<detailed_description>This non-interventional study determine rate control disease activity moderate severe IBD participant . The study enroll approximately 400 patient . This multicenter trial conduct Brazil . Retrospective data previous IBD treatment ( drug , dose , treatment duration , drug change ) , use health resource related management IBD previous three year collect . Prospective data collect period 12 month participant active disease . UC participant , light disease activity Day 1 continue 12-month follow . CD participant , light disease activity Day 1 colonoscopy calprotectin level ( i.e , calprotectin &gt; 200 ug/g ) previous year suggestive inadequate control activity progress 12-month follow .</detailed_description>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>1 . Male female . 2 . 18 year old ( time diagnosis moderate severe UC CD ) . 3 . Diagnosis moderate severe CD UC least 6 month prior Day 1 appointment accord clinical endoscopic criterion . 4 . Has provide write informed consent . For prospective period , eligible participant present least one follow criterion apply Day 1 : 5 . For CD participant : Harvey Bradshaw Index ( HBI ) ≥8 Crohn 's Disease Activity Index ( CDAI ) ≥220 Considering CD participant , disease activity may clearly document clinical data , objective criterion may consider entry criterion 12month prospective period : Colonoscopy previous year suggestive inadequate control activity , Calprotectin level previous year suggestive inadequate control activity ( i.e , calprotectin &gt; 200 µg/g ) . 6 . For UC : partial Mayo Score ≥5 . Note : Patients colostomy prospective period : Although clinical scale define impacted colostomy patient exclude protocol ensure assessment different clinical presentation IBD . In addition , patient colostomy must follow criterion eligible prospective phase . 1 . Indeterminate classify colitis . 2 . Current previous participation interventional clinical trial ( within last 3 year ) . In addition , 12month prospective period , participant exclude : 3 . Presenting mental incapacity , unwillingness language barrier preclude adequate understanding cooperation . 4 . Hospitalized participant Day 1 . 5 . Current label treatment Vedolizumab . Study Discontinuation Criteria It consider premature termination situation subject discontinues participation , i.e . withdrawn study complete 12 month follow period ( 365 day ± 14 day Day 1 ) , due reason list : 1 . Withdrawal consent : subject reason withdraw free informed consent ; 2 . Lost followup ( return subject expect date visit dropout protocol ) ; 3 . Death ; 4 . Study termination ; 5 . Any situation place subject within one exclusion criterion . Note : Patients eligible prospective period , mean , active disease Day 1 12 month period present disease remission and/or activity disease condition , allow continue participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>